



## **The subscription price for warrants series TO2 in Biosergen has been determined to SEK 0.66 and the exercise period starts on August 14, 2023**

Stockholm, Sweden - August 11, 2023 - Biosergen AB ("Biosergen" or the "Company") completed a rights issue of units on Nasdaq First North Growth Market in October 2022 (the "Rights Issue"). The exercise period for warrants series TO2 issued in conjunction with the Rights Issue begins on Monday, August 14, 2023. Each warrant series TO2 entitles to subscription of one (1) new share in the Company at an exercise price of SEK 0.66.

### **Summarized terms for warrants series TO2:**

**Exercise period:** August 14 – August 25, 2023.

**Issue size:** 8,595,531 warrants series TO2, which entitle to subscription of 8,595,531 shares. If all warrants are exercised, the Company will receive approximately SEK 5.7 million before issuing costs.

**Subscription price:** SEK 0.66 per share.

**Last day for trading warrants series TO2:** August 22, 2023.

**Share capital and dilution:** If all warrants are exercised, the share capital will increase with SEK 214,888.275, from SEK 1,060,691.500 to SEK 1,275,579.775, and the number of shares and votes in the Company will increase with 8,595,531, from 42,427,660 to 51,023,191. In the event that all warrants series TO2 are exercised, the dilution amounts to approximately 16.8 percent of the number of shares and votes in the Company.

Each unit in the Rights Issue consisted of five (5) shares and three (3) warrants series TO2. Each warrant series TO2 entitles to subscription of one (1) new share in the Company. The exercise price for warrants series TO2 has been determined as 70 percent of the volume-weighted average price of the Company's share on Nasdaq First North Growth Market during the measurement period, which ran from and including July 28, 2023, up to and including August 10, 2023. During the measurement period, the volume-weighted average price in the Company's share was approximately SEK 0.94, therefore, the exercise price for warrants series TO2 is SEK 0.66. The exercise period for warrants series TO2 runs during the period from and including August 14, 2023, up to and including August 25, 2023.

If all warrants series TO2 are exercised, the Company will receive approximately SEK 5.7 million before issuing costs. In order for the warrants not to expire and lose their value, it is required that the holder actively subscribes for new shares no later than August 25, 2023, or sells the warrants no later than August 22, 2023. Please observe that certain nominees might close their application earlier than August 25, 2023.

***Please note that warrants that are not exercised no later than August 25, 2023, or sold no later than August 22, 2023, will expire without value. For warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants.***

**How warrants are exercised:****Nominee-registered warrants (Custody account)**

Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Note that the nominees need your notification of the exercise of warrants series TO2 in time before the end of the exercise period. Please contact your nominee for additional information. Observe that certain nominees might close their application earlier than August 25, 2023.

**Direct-registered warrants (Securities account)**

The warrant holders who have warrants series TO2 in a VP-account subscribe directly via an application form. The application form is then to be submitted via e-mail to [emissioner@mangold.se](mailto:emissioner@mangold.se) or by mail according to instructions on the application form. Please contact the institute where you have your warrants registered for additional information.

The application form including instructions for payment will be available at the Company's website, [www.Biosergen.net](http://www.Biosergen.net).

**Advisors**

Mangold Fondkommission AB is the financial advisor and Setterwalls Advokatbyrå AB is the legal advisor to Biosergen in connection with the exercise of warrants series TO2.

**For further information about Biosergen, please contact:**

Dr. Peder M. Andersen, CEO

Telephone: +45 2080 2470

E-mail: [peder.andersen@biosergen.net](mailto:peder.andersen@biosergen.net)

Niels Lauren, CFO

Telephone: +45 4014 5059

E-mail: [niels.laursen@biosergen.net](mailto:niels.laursen@biosergen.net)

**Certified Adviser**

Erik Penser Bank

Telephone: +46 8 463 8000

E-mail: [certifiedadvisor@penser.se](mailto:certifiedadvisor@penser.se)

**About Biosergen**

Biosergen is a clinical stage biotechnology company that employs all its organizational and financial resources on the clinical development of BSG005. BSG005, a polyene macrolide, is a potentially disruptive antifungal drug with blockbuster potential based on significant safety and potency advantages over competing antifungals, including Amphotericin B, and being completely free of the kidney toxicity hampering other drugs in its class. The research behind BSG005 and its unique properties has been documented in over 20 peer reviewed scientific papers. Biosergen initially aims BSG005 towards invasive fungal infections that claim the lives of hundreds of thousands of immune-compromised AIDS-, cancer- and transplant patients every year. At equal dose levels BSG005 shows a three-to-fourfold potency advantage against relevant fungal strains compared to current standards of care. The Company is also developing BSG005 Nano where the drug is packed in special nano particles to specifically target the lung, often the first affected organ in an invasive fungal infection. BSG005 Nano Oral is an extension of BSG005 Nano. An oral formulation would greatly increase the usefulness, particularly as a prophylactic and as home treatment after transplants or cancer treatment to prevent invasive fungal infection. Biosergen is granted orphan drug status for BSG005 in the United States.

**Important information**

The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Biosergen. Invitation to the persons concerned to subscribe for units consisting of shares and warrants in Biosergen has only taken place through the prospectus that Biosergen published on September 13, 2022.